Mesoblast (MESO) IPO Opens Lower, Trades Back Above Flat-line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Mesoblast Announces Pricing Of Public Offering On Nasdaq
November 13, 2015 8:39 AM ESTNEW YORK and MELBOURNE, Australia, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO) (ASX: MSB), a world leader in the development of innovative cell-based medicines, today announced the pricing of its public offering of 7,479,617 American Depositary Shares (ADSs), at a public offering price of US$8.00 per ADS, before underwriting discounts and commissions. In addition, Mesoblast has granted the underwriters a 30-day option to purchase up to an additional 1,121,942 ADSs at the public offering price to cover over-allotments, if any. Mesoblast expects gross proceeds before deducting underwriting discounts and... More
